PuSH - Publikationsserver des Helmholtz Zentrums München

Vlot, A.H.C.* ; Aniceto, N.* ; Menden, M.P. ; Ulrich-Merzenich, G.* ; Bender, A.*

Applying synergy metrics to combination screening data: Agreements, disagreements and pitfalls.

Drug Discov. Today 24, 2286-2298 (2019)
Postprint DOI
Open Access Green
Synergistic drug combinations are commonly sought to overcome monotherapy resistance in cancer treatment. To identify such combinations, high-throughput cancer cell line combination screens are performed; and synergy is quantified using competing models based on fundamentally different assumptions. Here, we compare the behaviour of four synergy models, namely Loewe additivity, Bliss independence, highest single agent and zero interaction potency, using the Merck oncology combination screen. We evaluate agreements and disagreements between the models and investigate putative artefacts of each model's assumptions. Despite at least moderate concordance between scores (Pearson's r >0.32, Spearman's rho > 0.34), multiple instances of strong disagreement were observed. Those disagreements are driven by, among others, large differences in tested concentrations, maximum response values and median effective concentrations.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Drug Synergy
ISSN (print) / ISBN 1359-6446
e-ISSN 1878-5832
Zeitschrift Drug discovery today
Quellenangaben Band: 24, Heft: 12, Seiten: 2286-2298 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Cambridge
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Computational Biology (ICB)